The purchaser and end user assume full responsibility for proper handling, storage, regulatory compliance, and adherence to all applicable local and international laws governing research materials
For GI symptom management, adding BPC-157 during dose escalation makes sense
The non-antidepressant effects of citalopram: a clinicians perspective
Decision fatigue around food One underappreciated benefit of tirzepatide was that it reduced the mental energy spent thinking about food
Back in 2018, most of its earnings came from generics, with only a small share driven by innovation. Between 2025 and 2027, the company expects to bring dozens of major breakthroughs to market from GLP-1 therapies for obesity and diabetes to next-generation oncology treatments. Source: *Opinions are my own To view or add a comment, sign in Big Pharma News: Pfizer is set to acquire Metsera in a deal worth up to $4.9B Why it matters: $47.50/share upfront + $22.50/share tied to milestones Lead candidate MET-097i (GLP-1 therapy) showed 11.3% weight loss in 12 weeks Pipeline includes monthly amylin-based injections + oral obesity drugs Puts Pfizer head-to-head with Lilly & Novo Nordisk in the obesity race This move highlights the booming obesity drug market and pharmas growing appetite for metabolic innovation
10.1007/s00394-015-1063-2 97
